Go Pro

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services logo
$331.52 +3.33 (+1.01%)
Closing price 03:59 PM Eastern
Extended Trading
$332.50 +0.98 (+0.29%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
2
Buy
13

Based on 15 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 2 have given a hold rating, 11 have given a buy rating, and 2 have given a strong buy rating for WST.

Consensus Price Target

$364.42
9.92% Upside
According to the 15 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $364.42. The highest price target for WST is $447.00, while the lowest price target for WST is $295.00. The average price target represents a forecasted upside of 9.92% from the current price of $331.53.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

TypeCurrent Forecast
7/27/25 to 7/27/26
1 Month Ago
6/27/25 to 6/27/26
3 Months Ago
4/28/25 to 4/28/26
1 Year Ago
7/27/24 to 7/27/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$364.42$340.09$322.89$320.71
Forecasted Upside9.92% Upside-3.13% Downside10.33% Upside21.79% Upside
Consensus RatingBuyBuyModerate BuyModerate Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

West Pharmaceutical Services Stock vs. The Competition

TypeWest Pharmaceutical ServicesMedical CompaniesBroader Market
Consensus Rating Score
3.00
2.29
2.52
Consensus RatingBuyHoldModerate Buy
Predicted Upside8.65% Upside970.87% Upside13.10% Upside
News Sentiment Rating
Positive News

See Recent WST News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
7/24/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 Reiterated RatingHold (C)
7/15/2026
TD Cowen logo
TD Cowen
3 of 5 stars
 Reiterated RatingBuy
7/13/2026
BNP Paribas Exane logo
BNP Paribas Exane
5 of 5 stars
Curtis Moiles
Not Rated
Initiated CoverageOutperform$447.00+26.38%
7/9/2026Boost TargetEqual Weight$325.00 ➝ $365.00+2.02%
7/6/2026 Reiterated RatingOutperform$410.00+14.20%
7/2/2026Boost TargetOverweight$350.00 ➝ $390.00+6.84%
6/9/2026UpgradeEqual WeightOverweight$310.00 ➝ $400.00+25.01%
6/2/2026Reiterated RatingOverweight$360.00+13.97%
6/1/2026Initiated CoverageOutperform$375.00+18.72%
5/13/2026 UpgradeHoldStrong-Buy
4/24/2026 Reiterated RatingBuy
2/13/2026Reiterated RatingBuy$340.00+37.98%
2/13/2026Reiterated RatingBuy$315.00+29.70%
2/10/2026Reiterated RatingBuy$295.00+17.85%
9/15/2025Set Target$311.00+20.67%
12/13/2024 Boost TargetBuy$350.00 ➝ $355.00+8.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:14 PM ET.


Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 22, 2026. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • The company recently reported strong earnings, with earnings per share (EPS) significantly exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • West Pharmaceutical Services, Inc. has set ambitious guidance for FY 2026, projecting an EPS range that suggests continued growth and profitability, which can attract long-term investors.
  • The current stock price is around $305, reflecting a solid position in the market, which may appeal to investors looking for stability in the medical instruments sector.
  • With a net margin of nearly 17%, the company demonstrates effective cost management and profitability, which can lead to higher returns for shareholders.
  • West Pharmaceutical Services, Inc. is a key player in the pharmaceutical and biotech industries, focusing on high-quality packaging and delivery solutions, which positions it well for future growth as demand for injectable drugs increases.

West Pharmaceutical Services
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • Insider selling activity has been noted, with significant shares sold by executives, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, and while the current price is stable, any downturn could impact investor sentiment and lead to potential losses.
  • As a supplier to the pharmaceutical industry, West Pharmaceutical Services, Inc. is subject to regulatory changes and market volatility, which can pose risks to its business model.
  • Despite recent revenue growth, the competitive landscape in the medical instruments sector is intense, and maintaining market share can be challenging.
  • The company's reliance on the pharmaceutical and biotech industries means that any downturn in these sectors could adversely affect its financial performance.

WST Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $364.42, with a high forecast of $447.00 and a low forecast of $295.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 9.92% based on their 12-month stock forecasts.

Over the previous 90 days, West Pharmaceutical Services's stock had 3 upgrades by analysts.

West Pharmaceutical Services has been rated by research analysts at Barclays, BNP Paribas Exane, Evercore, KeyCorp, Morgan Stanley, Stephens, TD Cowen, Weiss Ratings, Wolfe Research, and Zacks Research in the past 90 days.

Analysts like West Pharmaceutical Services more than other "medical" companies. The consensus rating for West Pharmaceutical Services is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how WST compares to other companies.


This page (NYSE:WST) was last updated on 7/27/2026 by MarketBeat.com Staff.
From Our Partners